Bone marrow-derived mesenchymal stem cells for treatment of ischemic cardiomyopathy during artery bypass grafting

The aim of this study is to assess the safety and efficacy of allogenic bone marrow-derived mesenchymal stem cell (BM-MSC) implantation concomitant with coronary artery bypass grafting (CABG), to treat coronary artery disease and ischemic cardiomyopathy.